Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

QPS Holdings and Hepregen Corporation Announce Commercial Partnership

Published: Thursday, May 30, 2013
Last Updated: Monday, June 03, 2013
Bookmark and Share
The agreement provides co-promotion, marketing and sales of services utilizing Hepregen’s proprietary HepatoPac products.

QPS Holdings, LLC and Hepregen Corporation have announced the execution of an agreement between the companies that provides QPS a license to offer drug metabolism and pharmacokinetic (“DMPK”) services to its clients using Hepregen’s products. The agreement provides for offerings in both North America and Europe. The agreement also creates a marketing and sales partnership between the companies, providing for co-promotion of the HepatoPacTM-associated DMPK services. This arrangement is the first such partnership in the field for both companies. 

QPS expects to begin offering metabolite identification, profiling, and clearance studies to North American customers before the end of June, and to European customers in the third calendar quarter of this year using HepatoPacTM products. The North American services will be offered from its well established DMPK department in Newark, Delaware, and its newly established DMPK Hepatic Biosciences division based at the Hamner Institutes in Research Triangle Park, North Carolina, using rat, dog, monkey and human HepatoPacTM products. 

“Our ability to offer services utilizing Hepregen’s next-generation product portfolio is another demonstration of the QPS commitment to enhancing its leadership position in the ADME field, providing cutting-edge, liver-based in vitro services to the pharmaceutical and agrochemical industry,” stated Dr. Zamas Lam, QPS Senior Vice President of Preclinical Development. 

“QPS brings an extraordinary capability and expertise in bioanalytical technology and hepatic cell biology to our partnership and a strong commitment to a progressive vision in the growing field of hepatic sciences,” stated Dr. Vincent Zurawski, Hepregen’s Chief Executive. “Moreover, QPS is an exceptionally well-managed company, as demonstrated by its outstanding record of growth in the last five years. We are extremely pleased to be engaged with such a strong partner in this paradigm-shifting endeavor,” added Dr. Zurawski.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Hepregen Corporation and The Hamner Institutes for Health Sciences Announce Research Partnership
Agreement provides opportunity to collaborate on research supporting next generation in vitro micro-liver analysis associated with pharmaceutical and chemical product development.
Tuesday, August 13, 2013
Hepregen Announces Issuance of its First Patent
The patent protects manufacturing methods of Hepatopac and related products.
Tuesday, May 28, 2013
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Porphyrins as Catalysts in Scalable Organic Reactions
This review covers the most relevant scalable porphyrin-catalysed procedures, showing how these compounds represent broad applications in chemistry.
CDC Updates Zika Recommendations
CDC has issued updated Zika recommendations and guidance for healthcare providers with a focus on sexual transmission.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Genome of 6000-Year-Old Barley Sequenced
Researchers have successfully sequenced the genome of Chalcolithic barley grains for the first time.
3D Models May Yield Ovarian Cancer Insights
Researchers are developing new tools to decipher ovarian cancer developments through a 3D printing technology.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!